SCHEMBL18012883

SCHEMBL18012883

Oc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCOC(F)F

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 19/20 0.71
FBP1 P09467 2/20 0.61
ERBB2 P04626 2/20 0.60
AURKA O14965 1/20 0.60
INSR P06213 1/20 0.60
PDGFRB P09619 1/20 0.60
FLT4 P35916 1/20 0.60
KDR P35968 1/20 0.60
CLK1 P49759 1/20 0.60
EPHB4 P54760 1/20 0.60
TEK Q02763 1/20 0.60
AURKB Q96GD4 1/20 0.60
HDAC3 O15379 1/20 0.56
HDAC4 P56524 1/20 0.56
HDAC1 Q13547 1/20 0.56
HDAC7 Q8WUI4 1/20 0.56
HDAC2 Q92769 1/20 0.56
HDAC10 Q969S8 1/20 0.56
HDAC11 Q96DB2 1/20 0.56
HDAC8 Q9BY41 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18012075 0.92 FBP1 (0.72) EGFRFBP1ERBB2AURKAINSR
SCHEMBL18012076 0.88 EGFR (0.79) EGFRFBP1ERBB2AURKAINSR
SCHEMBL18013033 0.87 EGFR (0.69) EGFRFBP1KDRHDAC3HDAC4
SCHEMBL19125531 0.85 FBP1 (0.62) EGFRFBP1ERBB2AURKAINSR
SCHEMBL18013052 0.84 KDR (0.52) EGFRERBB2FLT4KDREPHB4
SCHEMBL3238800 0.83 EGFR (0.83) EGFRFBP1ERBB2AURKAINSR
SCHEMBL4229518 0.82 EGFR (0.69) EGFRFBP1ERBB2AURKAINSR
SCHEMBL18012092 0.82 EGFR (0.69) EGFRERBB2FLT4KDREPHB4
SCHEMBL18012884 0.82 EGFR (0.53) EGFRERBB2FLT4KDREPHB4
SCHEMBL18012880 0.82 ERBB2 (0.55) EGFRERBB2KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016123706-A1 NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS TRILLIUM THERAPEUTICS INC. (CA) 2016-08-11 WO disclosed